# Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-teneligliptin-40-mg-in-type-2-diabetes-a-pooled-analysis/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Takashi Kadowaki,Kazuyo Sasaki,Manabu Ishii,Miyuki Matsukawa,Yoshiteru Ushirogawa |
| Citations | 8 |
| DOI | 10.1007/s13300-018-0372-x |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://link.springer.com/content/pdf/10.1007%2Fs13300-018-0372-x.pdf |
| OpenAlex ID | https://openalex.org/W2792715720 |
| PMID | 29435909 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Miyuki Matsukawa](https://scholariq.org/researchers/miyuki-matsukawa/)

## Paper journal

- [Diabetes Therapy](https://scholariq.org/journals/diabetes-therapy/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.